<DOC>
	<DOCNO>NCT02261805</DOCNO>
	<brief_summary>This Phase I/safety dose expansion study combination drug ganetespib doxorubicin patient advance solid tumor . The purpose Phase I part study determine recommend phase II dose ganetespib give combination doxorubicin . The recommended Phase II dose determine end dose escalation phase use conduct safety dose expansion phase relapsed/refractory small cell lung cancer determine signal efficacy population .</brief_summary>
	<brief_title>A Phase I/II Study Ganetespib Combination With Doxorubicin</brief_title>
	<detailed_description>The dose escalation phase study follow standard 3+ 3 dose escalation scheme two dose level ganetespib ( 1 -- mg/m2 150 mg/m2 ) administer weekly Days 1 8 21-day cycle , combination fix dose doxorubicin 50 mg/m2 administer Day 1 alone . After 4-6 cycle combination therapy , continuation single agent ganetespib permit subject derive clinical benefit . Pharmacokinetic sample plasma drug level ganetespib collect pre-dose 4 hour completion treatment Day 1 Day 8 cycle 1 subject dose escalation phase . The recommended Phase II dose determine end dose escalation phase use conduct safety dose expansion phase relapsed/ refractory small cell lung cancer determine signal efficacy population .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Dose escalation phase : histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective . OR safety dose expansion phase : histologically cytologically confirm relapsed refractory small cell lung cancer No 3 prior line chemotherapy ; prior therapy doxorubicin permit lifetime cumulative dose 150 mg/m2 ; least 3 week since prior chemotherapy radiotherapy ; least 6 week last regimen include BCNU ( 1,3bis ( 2chloroethyl ) 1nitrosourea bischloronitrosourea ) mitomycin C Age &gt; /= 18 year ECOG ( Eastern Cooperative Oncology Group ) performance status 01 Life expectancy great 3 month Adequate organ marrow function Women childbearing potential must agree avoid become pregnant men must agree father child duration study participation . Ability understand willingness sign write informed consent document Chemotherapy radiotherapy within 3 week ( 6 week nitrosureas mitomycin C ) prior enter study recover adverse event due agent administer 3 week earlier . Receiving investigational agent Untreated symptomatic brain metastasis History allergic reaction attribute compound similar chemical biologic composition ganetespib agent use study Receiving medication substance strong inhibitor inducer CYP3A4 CYP2C18 Left ventricular ejection fraction &lt; 50 % Known serious cardiac illness medical condition uncontrolled intercurrent illness include , limited , ongoing active infection , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman HIVpositive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>